Table of Contents
Overview
New York, NY – June 18, 2025 – Global Infertility Treatment Market size is expected to be worth around US$ 3.98 Billion by 2034 from US$ 1.81 Billion in 2024, growing at a CAGR of 8.2% during the forecast period from 2025 to 2034. In 2024, Asia Pacific led the market, achieving over 39.2% share with a revenue of US$ 0.71 Billion.
The global infertility treatment market is witnessing substantial growth, driven by the increasing prevalence of infertility among men and women worldwide. According to the World Health Organization (WHO), over 17.5% of the adult population globally around 1 in 6 people experience infertility at some point in their lives, highlighting a significant public health concern.
Advances in assisted reproductive technologies (ART), such as in vitro fertilization (IVF), intrauterine insemination (IUI), and fertility medications, are playing a vital role in addressing this issue. These techniques are now more accessible due to supportive healthcare policies, improved insurance coverage, and growing awareness, especially in North America, Europe, and parts of Asia-Pacific.
The market is also benefiting from increasing investments in fertility clinics and diagnostic innovations, including hormone analysis, ovarian reserve testing, and genetic screening. Furthermore, delayed childbearing due to lifestyle changes, career priorities, and rising cases of conditions such as polycystic ovary syndrome (PCOS) are contributing to demand.
North America currently leads the market due to its advanced healthcare infrastructure and high ART utilization rates. However, emerging economies in Asia and Latin America are expected to show rapid growth owing to medical tourism, cost-effective treatment options, and expanding fertility services.
Key Takeaways
- Market Size: The global infertility treatment market is projected to grow significantly, reaching an estimated value of US$ 3.98 billion by 2034, up from US$ 1.81 billion in 2024. This expansion reflects a compound annual growth rate (CAGR) of 8.2% during the forecast period from 2025 to 2034.
- Product Segment Analysis: In 2024, the equipment segment emerged as the market leader, accounting for 36.4% of the total market share. This dominance can be attributed to the widespread adoption of advanced medical devices and instruments used in fertility treatment procedures.
- Procedure Segment Analysis: Among all treatment procedures, Assisted Reproductive Technology (ART) held the largest share in 2024, representing 34% of total revenues. This highlights the increasing reliance on laboratory-based fertilization techniques, such as in vitro fertilization (IVF), as preferred methods for addressing infertility.
- Gender-Based Analysis: In terms of gender segmentation, the female segment was dominant in 2024, contributing 34% of the total market revenue. This reflects the higher number of female-focused infertility evaluations and treatments, including ovulation induction and hormonal therapies.
- Regional Insights: The Asia Pacific region led the global infertility treatment market in 2024, with a market share of 39.2% and generating approximately US$ 0.71 billion in revenue. This regional growth is driven by increasing fertility awareness, expanding access to treatment facilities, and growing investments in reproductive health infrastructure.
Segmentation Analysis
- Product Type Analysis: In 2024, the infertility treatment market by product type was led by the equipment segment, holding 36.4% share due to high demand for IVF and cryopreservation systems. Consumables contributed 30%, including essential items like culture media and embryo transfer solutions. Software & Services accounted for 20%, driven by digital health tools and telemedicine. The accessories segment, comprising catheters and petri dishes, made up 13.6%, supporting procedural sterility and operational efficiency across clinics.
- Procedure Analysis: The market was segmented by procedure, with Assisted Reproductive Technology (ART) holding the top position in 2024 at 34% of total revenue, supported by high clinical success and rising IVF cycles. Artificial Insemination, including IUI, remained preferred for mild male infertility with up to 20% success per cycle. Fertility surgeries like laparoscopy captured a modest share. Hormone therapies and medications contributed around 20%, while other procedures, such as mitochondrial transfer, held under 10%.
- Gender Analysis: In 2024, the female segment led gender-based market revenue with a 34% share, due to high demand for IVF, hormone treatments, and laparoscopic procedures. Female infertility accounts for roughly one-third of global cases, as per NIH. The male segment is expanding, driven by ICSI, hormonal therapy, and semen diagnostics. NIH data also indicate one-third of infertility cases arise from male factors. Combined/unexplained infertility continues to generate demand for comprehensive, couple-based diagnostic and treatment approaches.
Market Segments
By Product Type
- Equipment
- Consumables
- Software & Services
- Accessories
By Procedure
- Assisted Reproductive Technology (ART)
- Artificial Insemination
- Fertility Surgeries
- Medications & Hormone Therapy
- Other Procedures
By Gender
- Male
- Female
Regional Analysis
In 2024, Asia Pacific emerged as the leading region in the global infertility treatment market, accounting for over 39.2% of total revenue and reaching a market value of approximately US$ 0.71 billion. This dominance is driven by increasing infertility rates linked to delayed parenthood, urban lifestyles, and environmental stressors. Rapid urbanization and work-related stress have heightened the demand for reproductive healthcare across major economies.
Governments in countries such as India, China, and Japan are actively promoting fertility awareness and expanding access to treatment through public health campaigns and financial support for assisted reproductive technologies (ART). Improved insurance coverage and enhanced public knowledge of infertility solutions are encouraging more individuals to seek medical intervention.
The presence of advanced healthcare infrastructure and availability of trained fertility specialists have supported the widespread adoption of procedures like IVF and ICSI. Additionally, nations such as South Korea and Singapore have established themselves as regional centers for fertility-related medical tourism, attracting international patients seeking cost-effective and high-quality care.
Key growth factors in Asia Pacific include high population density, declining birth rates, and increasing social acceptance of ART. Continued investment by regional health ministries in reproductive health programs and infrastructure further solidifies the region’s leadership in this market segment. Asia Pacific’s affordability, accessibility, and policy support remain central to its sustained growth.
Emerging Trends
- Rising Prevalence and Awareness: Recent data indicate that infertility affects approximately 17.5 % of adults worldwide about one in six people highlighting a growing global challenge and driving demand for expanded fertility services. Public health authorities are increasingly recognizing infertility as a disease requiring systematic intervention, leading to greater patient education and early screening programs in both high- and low-income settings.
- Expansion of Fertility Preservation: Assisted reproductive technology (ART) now routinely includes egg and embryo cryopreservation. In 2016, roughly 2 % of all ART cycles in the United States were performed to thaw and transfer previously frozen eggs, underscoring growing uptake of fertility-preservation strategies among individuals delaying childbearing for personal or medical reasons. Advances in vitrification techniques have improved post-thaw survival rates, making preservation more accessible and reliable.
- Enhanced Focus on Male Factor Infertility: Historically underdiagnosed, male factor infertility is gaining attention: WHO reports identify sperm quality issues such as low motility or abnormal morphology as leading causes in up to half of all infertility cases. This shift is prompting wider adoption of diagnostic semen analysis in primary care and expanded research into targeted male treatments, including antioxidant therapies and lifestyle-based interventions.
- Strengthened Public Policy and Funding Support: Governments and health ministries are launching new campaigns and subsidy programs to improve access to fertility care. For example, many countries now offer financial assistance for at least one cycle of ART, while public health advisories stress infertility screening as part of routine reproductive health. Such policy measures aim to reduce out-of-pocket costs and address disparities in treatment availability.
Use Cases
- Intrauterine Insemination (IUI) with Ovulation Induction: Medication-assisted IUI remains a first-line therapy for mild infertility. In women aged 35, a combined protocol using clomiphene citrate and IUI achieves per-cycle pregnancy rates of approximately 8.2%. This approach is favored for its lower cost and minimal invasiveness relative to full IVF, particularly in cases of unexplained infertility or mild male factor issues.
- In Vitro Fertilization (IVF) Volume and Reach: In 2019, U.S. fertility clinics performed 330 ,773 new ART cycles across 448 reporting centers, demonstrating the scale at which IVF services support couples facing infertility. These cycles encompass a range of procedures from conventional IVF to advanced techniques such as intracytoplasmic sperm injection (ICSI) and reflect broad patient access to specialized reproductive care.
- Cryopreservation-Based Treatments: Fertility preservation via egg and embryo freezing is increasingly integrated into oncology and elective care. Of ART cycles using frozen non-donor eggs in 2016, 26.3 % resulted in pregnancies and 21.3 % yielded live births after transfer, validating cryopreservation as an effective use case for both medical and social fertility preservation. These outcomes support expanded counseling for patients at risk of treatment-related ovarian damage or delaying parenthood.
Conclusion
The global infertility treatment market is poised for sustained growth, fueled by rising infertility prevalence, technological advancements in ART, and expanding access to reproductive care. Supportive public health policies, improved insurance coverage, and growing awareness are enabling broader adoption of fertility services across both developed and emerging regions.
Asia Pacific leads the market, while male infertility diagnostics, fertility preservation, and minimally invasive procedures continue to gain momentum. As infertility becomes increasingly recognized as a global health issue, continued investment in research, infrastructure, and equitable access will be critical in addressing unmet needs and improving outcomes for affected individuals worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
